healtheo360 Wellness Blog

Preeclampsia Awareness Month

Posted by healtheo360 on May 9, 2016 11:46:05 AM

About 76,000 pregnant women worldwide die each year from preeclampsia and other related hypertensive disorders. Preeclampsia awareness month helps to improve, educate, and raise awareness about maternal healthcare across the globe. The Preeclampsia Foundation’s theme for Preeclampsia Awareness Month 2016 is: The Faces of Preeclampsia: Any Woman, Any Pregnancy.

What is Preeclampsia?

Preeclampsia is a condition that occurs during pregnancy and postpartum that is characterized by high blood pressure and affects 5 to 8 % of all pregnancies. Preeclampsia typically occurs after 20 weeks of being pregnant. Women who are at risk for this medical condition are obese, became pregnant in their early teens or after the age of 40, have a family history of the disorder, or are carrying multiple babies.

Read Article

National Wear Red Day

Posted by healtheo360 on Feb 5, 2016 12:34:37 AM

 

Read Article

National Migraine and Headache Awareness Month

Posted by healtheo360 on Jun 23, 2015 10:47:06 AM

Did you know that 70 percent of all migraine sufferers are women? June is national migraine and headache awareness month. Throughout this month many people are helping one another to understand the symptoms, the causes, and to educate each other on how to prevent migraines and headaches in the future.

What is a Migraine and Headache?

Read Article

American Heart Month : Heart Disease in Women [Infographic]

Posted by healtheo360 on Feb 17, 2015 2:27:01 PM

1 in every 4 women dies from heart disease each year. It is important to catch the early signs of heart disease, however these signs are different in men and women. Currently, cardiovascular disease (CVD) affects 90% of adults and is the leading cause of death in women.

Read Article

FDA Approves Gardasil 9 Vaccine

Posted by healtheo360 on Dec 18, 2014 11:01:46 AM

This month the FDA approved Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) to be used for vaccination against nine types of the Human Papillomavirus (HPV). This new vaccination will be able to help prevent five more types of HPV than the previous vaccination, and will work to prevent 90% of cervical, vaginal, vulvar, and anal cancers. Although not yet available, the medical community is working on the release of the new vaccine for the near future.

HPV has a variety of types, and the vaccination works to prevent the types that most commonly lead to cancer. This new vaccination protects against types 16, 18, 31, 33, 45, 52 and 58. In the previous vaccine, only 16 and 18 were vaccinated against—and with Gardasil 9 an additional 20% of cervical cancers are now covered.

Read Article

The IUD: 5 Myths About This Birth Control

Posted by healtheo360 on Nov 13, 2014 11:33:28 AM

Recently the American Academy of Pediatrics declared the IUD the best form of birth control for young adults. IUDs are 99% effective at preventing unwanted pregnancy. However, even though the IUD is the most effective birth control on the market, it is only used by 9% of US women. This may be due to fears that the IUD has instilled in the minds of many Americans.

Read Article

HPV Vaccination Program in England a Success

Posted by healtheo360 on Apr 15, 2014 12:17:10 PM

MONDAY, April 14, 2014 (HealthDay News) -- A sharp drop in the number of young women infected with the two strains of human papillomavirus (HPV) most likely to cause cervical cancer occurred in England after the 2008 launch of a national vaccination program there, a new study shows.

Read Article

Advanced Cervical Cancer: Trial Therapy Offers New Hope

Posted by healtheo360 on Mar 12, 2014 11:15:15 AM

Keith Brofsky/Thinkstock(RIO DE JANEIRO) -- Researchers have made great strides in early detection and prevention for cervical cancer, the third-most common cancer in women, including the HPV vaccine. But with all the progress, there are still thousands of women with advanced disease, and the five-year survival rate for late-stage cervical cancer is 15 percent. That number may now climb dramatically, if the results of a trial for Erlotinib, now in its second phase, proves typical.

The standard care for advanced cervical cancer is chemo-radiation and Cisplatin, a nonspecific drug. Erlotinib, the epidermal growth factor receptor (EGFR) inhibitor, is a type of biologic medication targeting growth receptors in the cancerous cells -- they can’t grow and cancer recedes.

For the study, which is published in the journal Cancer, Brazilian researchers at the Instituto de Cancer in Rio de Janeiro conducted a small trial in 36 women with Stage II and III cervical cancer (which now has a survival rate of 40 percent). After 77 weeks of treatment, all but two patients saw a complete disappearance of the cancer. At two and three years out, 92 percent and 80 percent of women survived, respectively.

Side effects of Erlotinib were generally manageable with patients experiencing mostly rashes and diarrhea.

According to the study authors, this is the first study to show that a target agent has promising activity against locally advanced cervical cancer. Still, more research is needed as the data presented in the trial is only preliminary.

Copyright 2014 ABC News Radio

Read Article

Do Women Really Need Mammograms?

Posted by healtheo360 on Oct 23, 2013 12:32:16 AM

Do women need mammograms?

Read Article

healtheo360 Wellness Blog

Information & Resources for Patients, Caregivers, Family and Friends

healtheo360 offers you content that is useful, digestible, and easy on the eyes. We update this blog regularly with infographics and artilces covering topics that matter to our community members. So read on, enjoy, and share!

Subscribe to Email Updates

Recent Posts

Posts by Topic

see all